NCT01988077

Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Sheba Medical Center · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A rationally designed combination of adoptive T cell therapy and ipilimumab could strongly increase the proportion of CR patients, as well as the durability of response, as compared to ipilimumab or TIL alone. The investigators hypothesize that the combination of those two important modalities could result in a durable (≥ 1 year) complete response rate of 30% in stage IV melanoma patients.

Conditions

• A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response

Interventions

Type	Name	Description
BIOLOGICAL	Adoptive cell transfer	Adoptive cell transfer
DRUG	Ipilimumab 5 MG/ML Injection [Yervoy]	2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL

Timeline

• Start date: 2013-10-01
• Primary completion: 2016-05-20
• Completion: 2018-10-25
• First posted: 2013-11-20
• Last updated: 2019-04-05

Locations

1 site across 1 country: Israel